Nuvation Bio Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Nuvation Bio Inc. on August 12, 2021. The filing serves to announce the company's financial results for the quarter ended June 30, 2021. The company is incorporated in Delaware and trades on the New York Stock Exchange under the symbols NUVB (Class A Common Stock) and NUVB.WS (Redeemable Warrants).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. The document explicitly states that the information contained herein, including the referenced press release, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2021) for specific Q2 2021 financial figures.
- Verify the exercise price of the Redeemable Warrants ($11.50 per share) and their trading status.
- Confirm the company's status as an emerging growth company.
- Check subsequent filings for any updates to the financial results announced in this report.